Pegargiminase improves outcomes in nonepithelioid MPM

IF 81.1 1区 医学 Q1 ONCOLOGY Nature Reviews Clinical Oncology Pub Date : 2024-03-04 DOI:10.1038/s41571-024-00878-y
Peter Sidaway
{"title":"Pegargiminase improves outcomes in nonepithelioid MPM","authors":"Peter Sidaway","doi":"10.1038/s41571-024-00878-y","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":81.1000,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41571-024-00878-y","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
培加明酶(Pegargiminase)可改善非上皮样骨髓瘤的治疗效果
非上皮样恶性胸膜间皮瘤(MPMs)约占所有间皮瘤的三分之一,通常缺乏精氨酸琥珀酸合成酶 1(ASS1)功能(因此对外源精氨酸产生代谢依赖),因此容易受到减少精氨酸可用性的干预措施的影响。目前,来自 ATOMIC-Meso II/III 期试验的数据证明了培加明酶(ADI-PEG20)--一种改良的微生物酶--在这种情况下与化疗联合使用的疗效。共有 249 名经组织学证实为不可切除的非上皮样 MPM 患者被随机分配(1:1)接受肌肉注射培加明酶与安慰剂治疗,两者均与培美曲塞联合使用,外加顺铂或卡铂。由于担心现有抗ASS1抗体的准确性,因此没有选择缺乏ASS1的患者。总生存期(OS)是主要终点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
99.40
自引率
0.40%
发文量
114
审稿时长
6-12 weeks
期刊介绍: Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.
期刊最新文献
Expanding the use of T-DXd in metastatic HR-positive breast cancer: where are we now? On the cusp of targeted therapy for cancer cachexia — what clinical benefits might we promise our patients? Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia Author Correction: The high costs of anticancer therapies in the USA: challenges, opportunities and progress Cadonilimab is effective and safe in recurrent cervical cancer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1